On January 3, 2018 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), ("Onxeo" or the "Company"), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, reported that its management team will attend the following key investor and partnering conferences in the first half of 2018 (Press release, Onxeo, JAN 3, 2018, View Source [SID1234522855]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor meetings during the JP Morgan Healthcare Conference 2018
January 8-11, 2018
San Francisco, US

ODDO BHF Forum
January 12, 2018
Lyon, France

BIO-Europe Spring
March 12-14, 2018
Amsterdam, The Netherlands

CM-CIC Market Solutions Forum by ESN
March 22-23, 2018
Paris, France

Portzamparc MidCap 2018 Conference
April 4-5, 2018
Paris, France

BIO International Convention
June 4-7, 2018
Boston, US

SG CIB Nice Conference 2018
June 7-8, 2018
Nice, France

On January 3, 2018 FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), reported that Martin Meeson, President and COO of FUJIFILM Diosynth Biotechnologies U.S.A., is scheduled to present at EBD’s Biotech Showcase 2018 event during the 36th Annual J.P. Morgan Healthcare conference week in San Francisco, California (Press release, Fujifilm, JAN 3, 2018, View Source [SID1234522852]). The presentation is scheduled to take place Tuesday, Jan. 9, 2018 at 3:00 PM PST. The presentation will be part of the Yosemite -B Track (Ballroom Level).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Meeson’s presentation will focus on FUJIFILM Diosynth Biotechnologies’ investment strategies to support the growth and expansion required to meet the global demands in the delivery of biologics, gene and cell therapies.

The Biotech Showcase 2018 will take place at the Hilton San Francisco Union Square located at 333 O’Farrell Street – Ballroom Level, San Francisco, California 94102

On January 3, 2018 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Aron Knickerbocker, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 4:30 pm (PT) (Press release, Five Prime Therapeutics, JAN 3, 2018, View Source [SID1234522849]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source or directly at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

On January 3, 2018 Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, reported that President and Chief Executive Officer Jigar Raythatha will present a company overview at the 36th Annual JP Morgan Healthcare Conference on January 11 at 11:00 a.m. PST (2:00 p.m. EST), in room Elizabethan D (Press release, Constellation Pharmaceuticals, JAN 3, 2018, View Source [SID1234522848]). The conference is being held January 8-11 at the Westin St. Francis in San Francisco, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 3, 2018 ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 4:30pm PST (Press release, ChemoCentryx, JAN 3, 2018, View Source [SID1234522847]). The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company’s website for two weeks following the live presentation.